The Center for Genetic Engineering and Biotechnology (CIGB) has invited the global scientific community to participate in the International Congress on Biopharm Nonclinical Development, BioNCiD 2025, which will occur in Varadero Beach in late May, the institution announced on its website.

Havana, Cuba.- The CIGB, a leader in the research and development of biotechnology products in Cuba, stressed in its call that the event aims to bring together experts, academics, and industry professionals to discuss the latest breakthroughs in research for the nonclinical development of innovative biopharmaceuticals, promoting compliance with the 3Rs and the culture of care.

LEARN MORE
International Congress on Biopharm Nonclinical Development, BioNCiD 2025

The academic program will include topics such as non-clinical development programs for drugs and biopharmaceutical products, achievements in pharmacokinetics and toxicology, trends in the evaluation of drug-drug interactions, biopharmaceutical products, microbiota, and the update of the nonclinical regulatory framework. The program will also include staff training and facility accreditation.

Founded on July 1, 1986, the CIGB is a large research-production complex equipped with cutting-edge technology, significant production capacities, and staff engaged in the development of new products in all its phases, from the conception and expression of proteins with DNA recombination techniques to industrial-scale production and marketing of its products. (PL)